grade
pharmaceutical primary standard
API family
lithocholic acid
manufacturer/tradename
EDQM
mp
183-188 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
[H][C@]12CC[C@@]3([H])[C@]4([H])CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)CC[C@]3([H])[C@@]1(C)CC[C@@H](O)C2
InChI
1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17-,18+,19-,20+,21+,23+,24-/m1/s1
InChI key
SMEROWZSTRWXGI-HVATVPOCSA-N
Still not finding the right product?
Explore all of our products under 石胆酸
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Alan F Hofmann
Drug metabolism reviews, 36(3-4), 703-722 (2004-11-24)
Lithocholic acid, a monohydroxy, secondary bile acid, is formed by bacterial 7-dehydroxylation of the primary bile acid chenodeoxycholic acid (CDCA) and of the secondary bile acid ursodeoxycholic acid (UDCA). Lithocholic acid and its precursor CDCA are toxic when fed to
Matteo Incerti et al.
Journal of medicinal chemistry, 56(7), 2936-2947 (2013-03-16)
The Eph receptor-ephrin system is an emerging target for the development of novel antiangiogenetic agents. We recently identified lithocholic acid (LCA) as a small molecule able to block EphA2-dependent signals in cancer cells, suggesting that its (5β)-cholan-24-oic acid scaffold can
Simon M Vogel et al.
Proceedings of the National Academy of Sciences of the United States of America, 109(42), 16906-16910 (2012-10-05)
The proteins MDM2 and MDM4 are key negative regulators of the tumor suppressor protein p53, which are frequently upregulated in cancer cells. They inhibit the transactivation activity of p53 by binding separately or in concert to its transactivation domain. MDM2
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| L0720800 | 04061833812280 |